AstraZeneca Reports Revenue Growth Driven by Oncology Expansion and Restructuring Initiatives
AstraZeneca (AZN) reported strong financial performance through the first nine months of 2026, with total revenue growing 7% and core earnings per share increasing 14%. This growth is largely driven by successful product expansion in oncology and rare diseases, which helps mitigate revenue losses from expiring patents on cardiovascular drugs. A key highlight is the success of Tagrisso, which generated $2.1 billion in quarterly sales. To sustain long-term momentum, the company has launched a 'Reshaping for Sustainable Growth' initiative. This three-year restructuring program aims to deliver $1.5 billion in annualized pre-tax savings by streamlining clinical trials and operations, with funds being redeployed into R&D for cell therapies and weight management. Additionally, strategic partnerships, such as the collaboration with Summit Therapeutics, aim to bolster their antibody-drug conjugate (ADC) pipeline.
Topics: earnings report oncology R&D investment restructuring strategic partnership
Read the full article at Motley Fool
Part of the story Palantir Technologies Shares Decline Despite Record Q3 Revenue and Raised Guidance (16 articles)